



(12) Translation of
European patent specification

(11) NO/EP 3601266 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 403/12 (2006.01)
A61K 31/4196 (2006.01)
A61K 45/06 (2006.01)
A61P 31/12 (2006.01)
A61P 31/14 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2021.09.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.04.28
(86)	European Application Nr.	18715612.0
(86)	European Filing Date	2018.03.29
(87)	The European Application's Publication Date	2020.02.05
(30)	Priority	2017.03.31, EP, 17164048
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA ; MD ; TN
(73)	Proprietor	Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA Katholieke Universiteit Leuven, Waaistraat 6, bus 5105, 3000 Leuven, Belgium
(72)	Inventor	KESTELEYN, Bart Rudolf Romanie, c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse, Belgium BONFANTI, Jean-François, c/o Janssen-Cilag 1 rue Camille Desmoulins TSA 91003, 92787 Issy-les-Moulineaux Cedex 9, France COESEMANS, Erwin, c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse, Belgium RABOISSON, Pierre Jean-Marie Bernard, c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse, Belgium MARCHAND, Arnaud Didier M, c/o Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven (Heverlee), Belgium BARDIOT, Dorothée Alice Marie-Eve, c/o Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven (Heverlee), Belgium
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS
(56)	References Cited:	WO-A1-2014/154682, WO-A1-2013/045516

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Forbindelse som har formel (I)



hvor

R¹ er klor eller fluor,

R² er -CH₂CH₂OH eller C₃₋₅alkylCOOH;


- 10 R³ er trifluormetyl eller trifluormetoksy;











R⁴ er hydrogen, fluor eller metoksy; og

R⁵ er hydrogen eller metyl;

eller et farmasøytisk akseptabelt salt, solvat eller polymorf derav.

- 15 **2.** Forbindelse eller dens stereoisomere form, et farmasøytisk akseptabelt salt, solvat eller polymorf derav ifølge krav 1, hvor forbindelsen velges fra gruppen











5



3. Forbindelsen ifølge krav 1, hvori forbindelsen har (+) spesifikk rotasjon.

10


4. Forbindelsen ifølge krav 1, hvori forbindelsen velges fra:




15



5



eller



10

5. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 4 sammen med én eller flere farmasøytisk akseptable eksipienser, fortynningsmidler eller bærere.

15

6. Den farmasøytiske sammensetningen ifølge krav 5 som omfatter en andre eller ytterligere aktiv bestanddel.

7. Den farmasøytiske sammensetningen ifølge krav 6, hvori den andre eller ytterligere aktive bestanddelen er et antivirumiddel.

20

8. Forbindelse av formel (I) ifølge et hvilket som helst av kravene 1 til 4 for anvendelse som en medisin.

9. Forbindelse av formel (I) ifølge et hvilket som helst av kravene 1 til 4 for anvendelse
5 ved behandling av Dengue-infeksjon og for forebygging eller behandling av sykdom
forbundet med Dengue-infeksjon.

10. Forbindelse av formel (I) for anvendelse ifølge krav 9, hvori Dengue-infeksjonen er
infeksjon fra virus av stammen DENV-1, DENV-2, DENV-3 eller DENV-4.